In addition, pharmaceutical inhibition of the NFκB pathway by targeted drugs in relapsed primary MM samples ex vivo could be used to assess potential changes in BCL2A1/BFL-1, BCL2L1/BCL-XL, and BCL2/BCL-2 mRNA and protein expression. The gene discussed is BCL2L1; the disease is Miyoshi myopathy.